13 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 3.9% per year over the past 5 years.
Net income has grown faster than revenue (12.5% vs 3.9% per year).
Operating margin has expanded, at 16.5% in the latest year.
Free cash flow has declined 2.5% per year over the past 5 years.
Financial health
Operating income covered interest expense 4.3× in the latest year.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$21.3B
$2.4B
0.0%
16.5%
56.1%
8.0%
$2.5B
—
$2.9B
2024
$20.7B
$4.1B
0.0%
28.8%
97.4%
14.0%
$1.1B
—
$3.0B
2023
$20.6B
$1.3B
0.0%
12.2%
81.5%
4.6%
$1.6B
—
$1.2B
2022
$19.2B
$1.0B
0.0%
12.2%
87.7%
3.7%
$321M
—
$858M
2021
$19.5B
$1.5B
0.0%
14.7%
143.6%
5.4%
$910M
—
$2.4B
2020
$17.6B
—
0.0%
11.3%
0.0%
0.0%
$2.9B
—
$2.4B
2019
$18.5B
—
0.0%
8.3%
0.0%
0.0%
$563M
—
$262M
2018
$18.3B
—
0.0%
8.9%
0.0%
0.0%
$432M
—
$411M
2017
$20.6B
—
0.0%
5.4%
0.0%
0.0%
$493M
—
$611M
2016
$21.1B
—
0.0%
5.9%
0.0%
0.0%
-$317M
—
$716M
2010
—
$1.1B
—
—
63.4%
13.2%
—
$4.1B
$405M
2009
—
$181M
—
—
28.0%
2.3%
—
—
$690M
2008
—
$25M
—
—
—
—
—
—
$507M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Sep '26
$5.6B
$1.2B
0.0%
31.1%
22.4%
3.9%
$1.1B
—
$2.7B
Jun '26
$5.6B
$1.0B
0.0%
26.7%
22.4%
3.4%
$417M
—
$2.2B
Mar '26
$5.4B
$906M
0.0%
24.1%
18.8%
2.9%
$1.5B
—
$3.0B
Dec '25
$5.5B
$644M
0.0%
15.4%
15.3%
2.2%
$367M
—
$2.9B
Sep '25
$5.3B
$579M
0.0%
16.8%
14.4%
2.0%
$778M
—
$3.0B
Jun '25
$5.3B
$522M
0.0%
15.6%
13.9%
1.8%
$743M
—
$2.6B
Mar '25
$5.2B
$622M
0.0%
18.1%
14.9%
2.1%
$642M
—
$3.0B
Dec '24
$5.1B
$572M
0.0%
16.2%
13.7%
2.0%
-$661M
—
$3.0B
Sep '24
$5.1B
$681M
0.0%
21.2%
17.8%
2.3%
$829M
—
$4.1B
Jun '24
$5.1B
$477M
0.0%
14.9%
13.7%
1.6%
$602M
—
$2.9B
Mar '24
$5.4B
$2.3B
0.0%
61.2%
67.6%
8.1%
$346M
—
$2.5B
Dec '23
$5.4B
$456M
0.0%
13.7%
28.4%
1.6%
$616M
—
$1.2B
Sep '23
$5.1B
$266M
0.0%
11.2%
18.2%
1.0%
$327M
—
$1.1B
Jun '23
$5.1B
$293M
0.0%
11.9%
21.8%
1.1%
$466M
—
$934M
Mar '23
$5.0B
$296M
0.0%
12.0%
24.0%
1.1%
$214M
—
$766M
Dec '22
$5.0B
$274M
0.0%
10.7%
24.0%
1.0%
$131M
—
$858M
Sep '22
$4.8B
$268M
0.0%
12.4%
21.7%
1.0%
$150M
—
$1.2B
Jun '22
$4.6B
$179M
0.0%
11.9%
16.5%
0.7%
-$33M
—
$1.4B
Mar '22
$4.7B
$280M
0.0%
13.7%
26.5%
1.1%
$73M
—
$1.4B
Dec '21
$4.9B
$419M
0.0%
15.5%
40.8%
1.5%
$53M
—
$2.4B
Valuation over time
How the market has priced THC against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has risen from 4.7× (Mar '23) to 9.0× (Nov '26).
The price-to-sales ratio has risen from 0.2× (Mar '23) to 1.0× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is THC growing its revenue and profit?
Over the past 5 years, Tenet Healthcare Corp's revenue has grown 3.9% per year, and net income grown 12.5% per year. These are computed facts, not advice.
How much debt does THC have?
As of FY2025, Tenet Healthcare Corp reported — of total debt against $2.9B of cash; operating income covered interest expense 4.3×.
What is THC's profit margin?
In FY2025, gross margin was —, operating margin 16.5%, and net margin 11.1%.
What is THC's P/E ratio?
Tenet Healthcare Corp's P/E (TTM) is 5.60 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the THC stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 9.0× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.